ESMO review: advances in immunotherapy, EMA dialogue and pa...

QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s European Society for Medical Oncology (ESMO) congress in Copenhagen.

Infographic: Solving the challenges of immuno-oncology trial...

The booming interest in new targeted therapies represents a changing of the guard in cancer treatment, from the former one-size-fits-all approach to a more personalised methodology.

Cancer market commentary: Roche’s Tecentriq muscles into NSC...

BMS’s Opdivo and Merck’s Keytruda have been the sole PD-1 immunotherapies for the last two years, but Roche’s Tecentriq gained approval in May this year in urothelial carcinoma, a cancer of

Eye on ESMO: Day 2 - gamechangers take centre stage

Eye on ESMO: Day Three - Merck & Co. wins big lung cancer ba...

Day three at the European Society for Medical Oncology 2016 congress belonged to Merck & Co., and may well be seen as a hugely significant day in the future of lung cancer treatment.